Share on StockTwits

Veracyte (NASDAQ:VCYT) CFO Shelly D. Guyer sold 1,250 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $16.04, for a total value of $20,050.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Separately, analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday, June 19th. They set an “overweight” rating and a $21.00 price target on the stock. Four investment analysts have rated the stock with a buy rating, Veracyte currently has a consensus rating of “Buy” and a consensus target price of $20.50.

Veracyte (NASDAQ:VCYT) traded up 2.79% during mid-day trading on Tuesday, hitting $17.29. 20,907 shares of the company’s stock traded hands. Veracyte has a 1-year low of $10.88 and a 1-year high of $19.00. The stock’s 50-day moving average is $14.2 and its 200-day moving average is $14.93. The company’s market cap is $366.1 million.

Veracyte (NASDAQ:VCYT) last released its earnings data on Thursday, May 8th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter in the prior year, the company posted ($9.04) earnings per share. The company’s quarterly revenue was up 70.5% on a year-over-year basis. Analysts expect that Veracyte will post $-1.31 EPS for the current fiscal year.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.